References
- Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy. Immunotherapy 2011;3:629-35
- Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy 2017 [Epub ahead of print]
- Martignago I, Incorvaia C, Ridolo E. Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence. Clin Mol Allergy 2017;15:13
- Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J 2015;8:17
- Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172-7
- Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008;8:585-9
- Zhao Y, Feng HM, Qu J, et al. A systematic review of pharmacoeconomic guidelines. J Med Econ 2018;21:85-96
- Asaria M, Dhami S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy 2017 [Epub ahead of print]
- Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:27
- Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol 2012;130:1097-107
- Köberlein J, Mösges R. Oralair®: a causal treatment for grass pollen-induced allergic rhinoconjunctivitis. Immunotherapy 2013;5:13-21
- Manzotti G, Lombardi C. Allergen immunotherapy as a drug: the new deal of grass allergen tablets from clinical trials to current practice. Eur Ann Allergy Clin Immunol 2013;45:34-42
- Ivanova JI, Kelkar S, King S, et al. Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis. J Med Econ 2015;18:909-18
- Lombardi C, Melli V, Incorvaia C, et al. Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis. Clin Mol Allergy 2017;15:5
- Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis. Clin Drug Investig 2013;33:343-9
- Didier A, Wahn U, Horak F, et al. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol 2014;10:1309-24
- Westerhout KY, Verheggen BG, Schreder CH, et al. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012;15:906-17
- Verheggen BG, Westerhout KY, Schreder CH, et al. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy 2015;5:1
- Reinhold T, Brüggenjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. Allergo J Int 2017;26:7-15
- Brüggenjürgen B, Reinhold T. Cost-effectiveness of grass pollen SCIT compared to SLIT and symptomatic treatment in Austria, Spain and Switzerland. J Med Econ 2017;22:1-18
- Podladnikova J, Krcmova I, Vicek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2008;100:482-9